Atorvastatin calcium: FUTURE STUDIES(1)
Studies evaluating the outcomes of atorvastatin treatment in cardiovascular events are underway. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study is evaluating whether aggressive lipid lowering with atorvastatin commenced in the first few days following an acute coronary event effectively reduces the recurrence of subsequent ischemic events in patients with unstable angina or non-Q wave MI (personal communication). This international, placebo controlled trial is being conducted in over 2000 patients and is expected to be completed in 1998.
In the Aggressive Lipid Lowering with Atorvastatin Versus Revascularization Treatments (AVERT) study, atorvastatin is being investigated in a randomized trial determining whether aggressive lipid lowering therapy with atorvastatin is an alternative to angioplasty or catheter-based revascularization procedures or whether it may delay the need for these procedures in patients with significant CAD . This is also an international study of 18 months’ duration involving over 300 patients who have been randomly assigned to treatment with atorvastatin or revascularization followed by conventional care. Efficacy parameters to be measured include incidence rates of cardiac death, cardiac arrest, nonfatal MI, cerebrovascular accident, coronary artery bypass grafting, catheter-based revascularization or worsening of angina verified by objective evidence requiring hospitalization (including unstable angina). The study began in 1996, and results are expected in 1998. buy ortho tri-cyclen